Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3462817 in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of adult onset RA as defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 3 months prior to screening~* Have moderately to severely active RA defined by the presence of ≥6 swollen joints (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening and baseline. The distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility~* Have at least 1 of the following:~  * positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at screening, OR~ * previous radiographs documenting bony erosions in hands or feet consistent with RA~* Have C-reactive protein (CRP) \>1.2 times upper limit of normal (ULN) per the central laboratory at screening~* Demonstrated an inadequate response to, or loss of response or intolerance to:~  * at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment OR~ * at least 1 biologic DMARD/tsDMARD treatment~Exclusion Criteria:~* Class IV RA according to ACR revised response criteria~* Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of:~  * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or~ * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline~* Have presence of confirmed cervical dysplasia~* Have had various types of infection within 3 months of screening or develops any of these infections before the randomization visit.~* Have any of the following:~  * Human immunodeficiency virus (HIV) infection~ * Current infection with hepatitis B virus (HBV) (i.e., positive for hepatitis B surface antigen and/or polymerase chain reaction (PCR) positive for HBV DNA~ * Current infection with hepatitis C virus (HCV) (i.e., positive for HCV RNA)~ * Active tuberculosis (TB)~* Have failed more than 2 biologic DMARDs (bDMARDs) or tsDMARDs (e.g. excluded if have received 2 bDMARDs and 1 tsDMARD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3462817 300 mg (Type: EXPERIMENTAL): Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
- LY3462817 700 mg (Type: EXPERIMENTAL): Participants received IV infusion of 700 mg LY3462817 solution.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received IV infusion of 0.9% sodium chloride solution (Placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).